open access

Vol 62, No 1 (2011)
Original papers
Published online: 2011-03-01
Submitted: 2013-02-15
Get Citation

Switching from one generic alendronate to another - a common procedure in Poland in the years 2001-2005

Edward Franek, Marek Tałałaj, Hanna Wichrowska, Beata Czerwieńska, Rafał Filip, Krzysztof Safranow, Ewa Marcinowska-Suchowierska, Andrzej Więcek
Endokrynologia Polska 2011;62(1):14-17.

open access

Vol 62, No 1 (2011)
Original papers
Published online: 2011-03-01
Submitted: 2013-02-15

Abstract


Introduction: In clinical ambulatory practice, patients often, rather than discontinuing treatment, change to another one. This study aims to assess the reasons why patients with osteoporosis switch from one alendronate to another with a different brand name.
Material and methods: A retrospective analysis of 747 bisphosphonate-treated patients was performed (651 female, average age 67.3 ± 8.9 years, BMI 26.5 ± 4.0 kg/m2). The frequency and reasons for drug switching during the 19.4 ± 13.4 months of observation were analysed.
Results: In 387 (51.8%) patients, treatment was not changed during the observation period, whereas in 360 (48.2%) patients, at least one drug switch occurred. Almost 40% of patients from that group (138 patients) switched from one alendronate to another alendronate with a different brand name. The most frequent reasons were: adverse event (36.9%), high price of the drug (23.2%) and request of patient (16.7%).
Conclusions: A substantial proportion of persistent bisphosphonate-treated patients switch treatment from one alendronate to another. The most frequent reasons for that kind of switching are the occurrence of an adverse event and the high cost of treatment. (Pol J Endocrinol 2011; 62 (1): 14-17)

Abstract


Introduction: In clinical ambulatory practice, patients often, rather than discontinuing treatment, change to another one. This study aims to assess the reasons why patients with osteoporosis switch from one alendronate to another with a different brand name.
Material and methods: A retrospective analysis of 747 bisphosphonate-treated patients was performed (651 female, average age 67.3 ± 8.9 years, BMI 26.5 ± 4.0 kg/m2). The frequency and reasons for drug switching during the 19.4 ± 13.4 months of observation were analysed.
Results: In 387 (51.8%) patients, treatment was not changed during the observation period, whereas in 360 (48.2%) patients, at least one drug switch occurred. Almost 40% of patients from that group (138 patients) switched from one alendronate to another alendronate with a different brand name. The most frequent reasons were: adverse event (36.9%), high price of the drug (23.2%) and request of patient (16.7%).
Conclusions: A substantial proportion of persistent bisphosphonate-treated patients switch treatment from one alendronate to another. The most frequent reasons for that kind of switching are the occurrence of an adverse event and the high cost of treatment. (Pol J Endocrinol 2011; 62 (1): 14-17)
Get Citation

Keywords

osteoporosis; alendronate; adherence; persistence; compliance; switching

About this article
Title

Switching from one generic alendronate to another - a common procedure in Poland in the years 2001-2005

Journal

Endokrynologia Polska

Issue

Vol 62, No 1 (2011)

Pages

14-17

Published online

2011-03-01

Bibliographic record

Endokrynologia Polska 2011;62(1):14-17.

Keywords

osteoporosis
alendronate
adherence
persistence
compliance
switching

Authors

Edward Franek
Marek Tałałaj
Hanna Wichrowska
Beata Czerwieńska
Rafał Filip
Krzysztof Safranow
Ewa Marcinowska-Suchowierska
Andrzej Więcek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl